Alternatively, approaches for inhibiting Bcl‐xL or Mcl‐1 while avoiding thrombocytopenia or cardiac toxicity include the use of proteolysis‐targeting chimeras (PROTAC) that cause degradation of their target in a tissue‐specific manner [51, 52] or antibody‐drug conjugates (ADC) that selectively deliver the inhibitor to the tumor cells [53]. The gene discussed is MCL1; the disease is Thrombocytopenia.